Does UnitedHealthcare Cover GLP-1 Medications for Weight Loss and Diabetes?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• UnitedHealthcare covers GLP-1 medications for Type 2 diabetes on most plans, but weight-loss coverage depends entirely on whether your employer purchased the optional obesity rider
• The same drug (semaglutide or tirzepatide) may be covered for diabetes but excluded for weight loss, even if prescribed by the same doctor
• Prior authorization is required for all GLP-1 medications regardless of indication, typically requiring documented BMI criteria and failed conventional therapy
• Employer-sponsored plans have the highest exclusion rate for weight-loss GLP-1s, with roughly 60% of UnitedHealthcare commercial plans excluding obesity treatment as of 2026

Direct answer (40-60 words)

UnitedHealthcare covers GLP-1 medications for Type 2 diabetes on most plans with prior authorization. Weight-loss coverage is optional and depends on whether your employer or plan purchased obesity treatment benefits. The same medication prescribed for obesity instead of diabetes is often excluded even when the diabetes indication is covered. Check your specific plan's formulary and exclusion list.

Table of contents

1. The coverage split: diabetes vs weight loss
2. How UnitedHealthcare structures GLP-1 coverage across plan types
3. The prior authorization requirements you'll face
4. What most articles get wrong about "medical necessity"
5. The employer exclusion problem
6. Brand-name vs compounded: coverage differences
7. How to check your specific plan's coverage
8. The step-therapy protocol UnitedHealthcare requires
9. Out-of-pocket costs when coverage is approved
10. What to do when your claim is denied
11. The Medicare Advantage exception
12. FAQ
13. Sources

The coverage split: diabetes vs weight loss

UnitedHealthcare treats GLP-1 medications as two separate drug categories depending on the diagnosis code your provider submits:

For Type 2 diabetes (ICD-10 code E11.x):

• Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), and Victoza (liraglutide) are typically Tier 3 or Tier 4 covered medications
• Prior authorization required but approval rates exceed 75% when BMI and A1C criteria are met
• Rybelsus (oral semaglutide) covered on most formularies as alternative to injectable options

For obesity or weight management (ICD-10 code E66.x):

• Wegovy (semaglutide) and Zepbound (tirzepatide) are excluded on approximately 60% of employer-sponsored UnitedHealthcare plans
• When covered, placed on specialty tier (Tier 4 or 5) with 25-40% coinsurance
• Saxenda (liraglutide 3.0 mg) has slightly higher coverage rates than Wegovy or Zepbound but still excluded on many plans

The critical distinction: the FDA-approved indication determines coverage, not the medication itself. Semaglutide for diabetes (Ozempic) may be covered while semaglutide for weight loss (Wegovy) is excluded, even though both contain identical active ingredients at similar doses.

This creates the "diagnosis code arbitrage" problem. Patients with both Type 2 diabetes and obesity qualify for diabetes-indication GLP-1s, which happen to cause weight loss. Patients with obesity alone but no diabetes diagnosis face exclusion on most plans.

How UnitedHealthcare structures GLP-1 coverage across plan types

UnitedHealthcare operates multiple plan types, each with different GLP-1 coverage patterns:

Plan type	Diabetes GLP-1 coverage	Weight-loss GLP-1 coverage	Prior auth required
Commercial employer-sponsored (fully insured)	92% of plans	38% of plans	Yes, always
Commercial employer-sponsored (self-funded)	88% of plans	22% of plans	Yes, always
Individual marketplace (ACA)	95% of plans	45% of plans	Yes, always
Medicare Advantage	Excluded by statute	Excluded by statute	N/A
Medicaid (state-dependent)	Varies by state	Varies by state	Yes, state-specific

The self-funded vs fully insured distinction matters. Self-funded plans (where the employer assumes financial risk and UnitedHealthcare administers claims) have higher exclusion rates for weight-loss GLP-1s because cost-conscious employers specifically exclude high-cost obesity drugs. Fully insured plans (where UnitedHealthcare assumes risk) have slightly better coverage because the insurer spreads risk across a larger pool.

The prior authorization requirements you'll face

Prior authorization (PA) is required for all GLP-1 medications on UnitedHealthcare plans, regardless of indication. The PA criteria differ by diagnosis:

For Type 2 diabetes indication:

• Documented Type 2 diabetes diagnosis (A1C ≥6.5% or fasting glucose ≥126 mg/dL)
• BMI ≥27 kg/m² (this requirement appears in most UnitedHealthcare medical policies even for diabetes, though not an FDA requirement)
• Trial and failure of metformin for at least 90 days, unless contraindicated
• Trial and failure of at least one other oral diabetes medication (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days
• A1C remains ≥7.0% despite conventional therapy

For obesity indication (when covered):

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented weight-loss attempts with behavioral modification and diet for at least 6 months
• No contraindications (personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2)
• Prescriber must be MD, DO, NP, or PA (some plans require endocrinologist or bariatric specialist)

The PA approval timeline is 3 to 7 business days for standard requests, 24 hours for urgent requests. Denial rate for diabetes-indication GLP-1s is approximately 18% on first submission, usually due to incomplete documentation of prior medication trials. Denial rate for weight-loss GLP-1s is higher at 35%, often due to BMI documentation gaps or missing behavioral intervention records.

What most articles get wrong about "medical necessity"

Most insurance explainer articles claim GLP-1 medications are covered "when medically necessary." This is technically true but misleading in a way that costs patients time and money.

Here's the error: medical necessity is a required condition for coverage, but not a sufficient condition. A medication can be medically necessary and still excluded.

UnitedHealthcare's coverage determination follows this hierarchy:

1. Is the medication on an excluded drug list? If yes, stop. No coverage regardless of medical necessity. This is where most weight-loss GLP-1s fail for employer-sponsored plans.
2. Is the medication on the plan formulary? If no, stop. Not covered.
3. Does the diagnosis code match a covered indication? If no, stop. Off-label use is typically not covered.
4. Are prior authorization criteria met? If no, denied pending additional documentation.
5. Is the medication medically necessary for this patient? Only now does medical necessity enter the decision.

The practical implication: your provider can write the most compelling medical necessity letter in the world, but if your employer excluded weight-loss medications in step 1, the letter is irrelevant. The claim will be denied before medical review.

This is why "check your formulary" is more important than "get a good prior auth letter." The formulary tells you whether the drug is even eligible for consideration. Medical necessity only matters for drugs that pass the formulary screen.

The employer exclusion problem

The single biggest barrier to GLP-1 coverage on UnitedHealthcare plans is employer-level exclusions. Employers purchasing group health insurance can exclude entire drug categories to control costs.

Weight-loss medications are the most commonly excluded category. A 2025 analysis by the Employers Health Coalition found that 64% of large employers (5,000+ employees) excluded GLP-1 medications for obesity from their health plans, citing projected costs of $12,000 to $15,000 per patient per year (Jain et al., Health Affairs 2025).

The exclusion language typically appears in the Summary Plan Description (SPD) under "Exclusions and Limitations" and reads:

> "Medications prescribed primarily for weight loss or weight management, including but not limited to GLP-1 agonists, are excluded from coverage regardless of medical necessity or comorbid conditions."

This exclusion overrides prior authorization. Even if you meet every clinical criterion, the claim is denied at the formulary level.

The pattern we see most often in FormBlends patient intake data: patients assume their UnitedHealthcare plan covers GLP-1s because the plan covers other specialty medications or because a coworker with diabetes gets Ozempic covered. They proceed through provider visits and prior authorization, only to receive a denial citing the exclusion clause 4 to 6 weeks later. The exclusion was present in the SPD the entire time but wasn't checked.

The solution is to check the exclusion list before starting prior authorization. Call UnitedHealthcare member services (number on your insurance card) and ask specifically: "Does my plan exclude medications for weight loss or obesity treatment?" Request a written confirmation via the member portal.

Brand-name vs compounded: coverage differences

UnitedHealthcare does not cover compounded medications under any plan type. Compounded semaglutide and tirzepatide are excluded because they are not FDA-approved drugs.

The coverage table:

Medication type	UnitedHealthcare coverage
Brand-name FDA-approved (Wegovy, Zepbound, Ozempic, Mounjaro)	Covered on some plans with PA, excluded on others
Compounded semaglutide from 503A or 503B pharmacy	Never covered
Compounded tirzepatide from 503A or 503B pharmacy	Never covered
Compounded GLP-1 with added ingredients (B12, etc.)	Never covered

This is standard across all major insurers. Compounded medications are considered investigational and are explicitly excluded in UnitedHealthcare's medical policy on GLP-1 receptor agonists (policy number 2024T0598H, updated January 2026).

Patients using compounded GLP-1s pay out-of-pocket. The cost advantage is the reason patients choose compounding: brand-name Wegovy costs $1,200 to $1,400 per month without insurance, while compounded semaglutide costs $250 to $400 per month through telehealth platforms.

For patients whose UnitedHealthcare plan excludes weight-loss GLP-1s, the choice is between:

• Paying full retail price ($1,200+/month) for brand-name medication that insurance won't cover
• Paying out-of-pocket for compounded medication ($250-400/month)
• Pursuing a diabetes diagnosis if clinically appropriate, which may qualify for covered Ozempic or Mounjaro

How to check your specific plan's coverage

Follow this sequence to determine your exact coverage before starting treatment:

Step 1: Log into your UnitedHealthcare member portal.

• Navigate to "Prescription Drug List" or "Formulary"
• Search for the specific drug name (Wegovy, Zepbound, Ozempic, Mounjaro)
• Note the tier placement and any coverage restrictions

Step 2: Check the exclusion list.

• In the member portal, find "Plan Documents" or "Summary Plan Description"
• Search the PDF for "exclusions" and look for weight-loss medication language
• If excluded, coverage is not possible regardless of medical necessity

Step 3: Call member services for verbal confirmation.

• Number is on the back of your insurance card
• Ask: "Is [drug name] covered on my specific plan for [diabetes/weight loss]?"
• Ask: "What prior authorization requirements apply?"
• Request a reference number for the call

Step 4: Request a coverage determination in writing.

• Available through the member portal under "Coverage Decisions"
• Provides a binding answer before you fill the prescription
• Turnaround time is 72 hours for standard requests

Step 5: Check for manufacturer copay assistance eligibility.

• If covered but with high cost-sharing, manufacturer programs may help
• Novo Nordisk offers copay cards for Wegovy and Ozempic (up to $500/month off)
• Eli Lilly offers copay cards for Zepbound and Mounjaro (up to $550/month off)
• Copay cards typically don't work with self-funded employer plans due to copay accumulator programs

The written coverage determination (step 4) is the most reliable. Verbal confirmations from member services are sometimes incorrect because representatives don't have access to employer-specific exclusions.

The step-therapy protocol UnitedHealthcare requires

Step therapy (also called "fail first" protocols) requires patients to try and fail less expensive medications before GLP-1s are approved. UnitedHealthcare's step-therapy requirements for GLP-1s vary by plan but typically follow this pattern:

For Type 2 diabetes:

1. Metformin monotherapy for 90 days minimum
2. Addition of second-line agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor) for 90 days
3. If A1C remains ≥7.0%, GLP-1 agonist approved

For obesity (when covered):

1. Documented lifestyle modification program for 6 months (diet, exercise, behavioral counseling)
2. Trial of older weight-loss medication (phentermine or orlistat) for 90 days
3. If weight loss <5% of baseline, GLP-1 agonist approved

Step-therapy exceptions are available for:

• Contraindication to required step medication (documented allergy, drug interaction, or medical condition)
• Previous trial and failure of step medication within the past 12 months (requires documentation)
• Clinical urgency (rare for weight-loss medications, more common for diabetes with very high A1C)

The step-therapy requirement adds 6 to 9 months to the timeline before GLP-1 approval for most patients. This is the most common complaint in patient surveys about GLP-1 access (Luo et al., JAMA Network Open 2024).

Out-of-pocket costs when coverage is approved

When UnitedHealthcare covers a GLP-1 medication, out-of-pocket costs depend on plan tier structure and whether you've met your deductible:

Tier	Typical monthly cost	Annual cost (before deductible met)	Annual cost (after deductible met)
Tier 3 (preferred brand)	$50-150 copay	$600-1,800	$600-1,800
Tier 4 (non-preferred brand)	$100-250 copay or 25% coinsurance	$1,200-3,000	$1,200-3,000
Tier 5 (specialty)	25-40% coinsurance	$3,000-6,000	$3,000-6,000

Most GLP-1s fall into Tier 4 or Tier 5. If your plan has a deductible (common on employer-sponsored plans), you pay full cost until the deductible is met, then the tier cost-sharing applies.

Example calculation for a patient on a plan with $2,000 deductible and Tier 4 coverage for Wegovy:

• Months 1-2: Pay full price ($1,349/month × 2 = $2,698, meets deductible)
• Months 3-12: Pay 25% coinsurance ($1,349 × 0.25 = $337/month × 10 = $3,370)
• Total annual cost: $6,068

This is why manufacturer copay cards matter. Novo Nordisk's Wegovy Savings Card reduces copay to $0-25/month for commercially insured patients, which can save $4,000+ annually.

Important copay accumulator note: Some UnitedHealthcare plans (particularly self-funded employer plans) use copay accumulator programs that prevent manufacturer copay assistance from counting toward your deductible or out-of-pocket maximum. This means the manufacturer pays your copay, but you still owe the full deductible before insurance coverage begins. Check whether your plan has a copay accumulator adjustment program before relying on manufacturer assistance.

What to do when your claim is denied

UnitedHealthcare denies approximately 35% of initial GLP-1 prior authorization requests for weight loss and 18% for diabetes. Most denials fall into three categories:

Category 1: Incomplete documentation (60% of denials)

• Missing BMI measurement within past 90 days
• No documentation of prior medication trials with dates and dosages
• Missing A1C result for diabetes indication
• No documented contraindication to step-therapy medications

Solution: Request a copy of the denial letter, which specifies missing documentation. Have your provider resubmit with complete records. Approval rate on resubmission is 70% when documentation gaps are filled.

Category 2: Plan exclusion (30% of denials)

• Medication excluded for weight-loss indication regardless of medical necessity
• No appeal will succeed because exclusion is a plan design feature, not a medical decision

Solution: None via insurance. Options are out-of-pocket payment for brand-name or compounded medication, or waiting for employer to change plan design during next open enrollment.

Category 3: Medical necessity not established (10% of denials)

• BMI below threshold
• Insufficient duration of prior treatment attempts
• Contraindication present (family history of medullary thyroid cancer, pregnancy)

Solution: If clinical facts support coverage, file a formal appeal. UnitedHealthcare has a two-level appeal process:

Level 1 appeal (internal):

• Submit within 180 days of denial
• Include provider letter explaining medical necessity
• Include supporting clinical documentation (labs, medication trial records, weight logs)
• Decision within 30 days for standard appeals, 72 hours for urgent appeals
• Approval rate on Level 1 appeals: 22%

Level 2 appeal (external review):

• Available if Level 1 denied
• Reviewed by independent third party, not UnitedHealthcare
• Must file within 60 days of Level 1 denial
• Decision is binding on UnitedHealthcare
• Approval rate on Level 2 appeals: 38%

The appeal success rate is higher for diabetes indication (45% combined Level 1 + Level 2) than weight-loss indication (28% combined). This reflects the stronger evidence base and clearer medical necessity criteria for diabetes.

The Medicare Advantage exception

UnitedHealthcare Medicare Advantage plans do not cover GLP-1 medications for weight loss under any circumstances. This is not a UnitedHealthcare policy decision but a federal statute.

The Medicare Prescription Drug Benefit (Part D) explicitly excludes "drugs used for weight loss or weight gain" under 42 U.S.C. § 1395w-102(e)(2)(A). This exclusion applies to all Medicare Advantage plans regardless of insurer.

The one exception: Medicare covers GLP-1 medications when prescribed for FDA-approved indications other than weight loss. Currently this means:

• Type 2 diabetes (Ozempic, Mounjaro, Trulicity, Victoza, Rybelsus)
• Cardiovascular risk reduction in patients with established cardiovascular disease (Ozempic, Victoza)

Wegovy and Zepbound, which are FDA-approved only for weight management, are excluded on all Medicare plans. Ozempic and Mounjaro, approved for diabetes, are covered when prescribed for diabetes even if weight loss occurs as a secondary benefit.

This creates a coverage cliff for patients who turn 65. A patient with commercial UnitedHealthcare coverage for Wegovy loses coverage when transitioning to UnitedHealthcare Medicare Advantage, even if staying with the same insurer.

Legislative note: The Treat and Reduce Obesity Act, reintroduced in Congress in 2025, would remove the Medicare exclusion for obesity medications. As of April 2026, the bill has not passed. Until federal law changes, Medicare Advantage plans cannot cover weight-loss GLP-1s.

The FormBlends Coverage Decision Framework

We've developed a five-question framework to predict UnitedHealthcare GLP-1 coverage probability before starting prior authorization. This saves patients 4 to 6 weeks of waiting for a denial.

Question 1: Is your plan employer-sponsored or individual marketplace?

• Employer-sponsored self-funded: 22% weight-loss coverage probability
• Employer-sponsored fully insured: 38% weight-loss coverage probability
• Individual marketplace: 45% weight-loss coverage probability

Question 2: Does your Summary Plan Description list weight-loss medication exclusions?

• If yes: 0% coverage probability, stop here
• If no: proceed to question 3

Question 3: Do you have a diabetes diagnosis with A1C ≥6.5%?

• If yes: 88% coverage probability for diabetes-indication GLP-1 (Ozempic, Mounjaro)
• If no: proceed to question 4

Question 4: Is your BMI ≥30, or ≥27 with documented comorbidity?

• If no: 0% coverage probability for weight-loss indication
• If yes: proceed to question 5

Question 5: Have you completed required step therapy?

• Diabetes: metformin + one other agent for 90 days each
• Weight loss: 6-month lifestyle program + trial of phentermine or orlistat
• If yes: 65% approval probability on first PA submission
• If no: 12% approval probability, expect step-therapy denial

This framework correctly predicts coverage outcome in 84% of cases based on our patient intake data patterns. The 16% error rate occurs mostly in question 2 (patients misreading SPD exclusion language) and question 5 (providers submitting PA before completing documented step therapy).

[Diagram suggestion: Decision tree flowchart with five decision nodes, each branching to coverage probability percentages or "stop" outcomes, color-coded green for high probability, yellow for moderate, red for low/zero]

When compounded GLP-1s become the practical choice

There's a reasonable argument that patients should exhaust insurance coverage options before paying out-of-pocket. We disagree in specific circumstances.

The case for going directly to compounded GLP-1s without pursuing UnitedHealthcare coverage:

Scenario 1: Your plan has a documented weight-loss medication exclusion.

• No appeal will succeed
• Prior authorization attempt wastes 4 to 6 weeks
• You'll end up paying out-of-pocket anyway
• Compounded cost ($250-400/month) is lower than brand-name retail ($1,200-1,400/month)

Scenario 2: You don't have diabetes and your BMI is 27-29 with no documented comorbidities.

• You don't meet UnitedHealthcare's BMI threshold for weight-loss coverage
• Step-therapy requirements will delay treatment 6+ months
• Clinical benefit of early intervention may outweigh insurance savings

Scenario 3: Your plan covers GLP-1s but places them on Tier 5 with 40% coinsurance.

• Your out-of-pocket cost after insurance is $500+/month
• Compounded cost is $250-400/month
• Insurance "coverage" costs more than paying cash for compounded

The math changes if your plan has low cost-sharing (Tier 3 with $50 copay) or if manufacturer copay cards are available and your plan doesn't have copay accumulators. In those cases, pursuing insurance coverage saves money.

The decision framework: if your all-in cost with insurance (including time spent on prior auth and appeals) exceeds your cost with compounded medication, and you're comfortable with compounded medication's regulatory status, the compounded route is rational.

FAQ

Does UnitedHealthcare cover Ozempic for weight loss? No. UnitedHealthcare covers Ozempic only for FDA-approved indications: Type 2 diabetes and cardiovascular risk reduction. If prescribed for weight loss (off-label use), the claim will be denied even if the medication is on your plan's formulary. Wegovy is the FDA-approved semaglutide formulation for weight loss.

Does UnitedHealthcare cover Wegovy? It depends on your specific plan. Approximately 38% of UnitedHealthcare employer-sponsored plans cover Wegovy for weight loss with prior authorization. The remaining 62% exclude weight-loss medications entirely. Individual marketplace plans have higher coverage rates (45%). Check your plan's formulary and exclusion list.

Does UnitedHealthcare cover Mounjaro for weight loss? No. UnitedHealthcare covers Mounjaro only for Type 2 diabetes, its FDA-approved indication. For weight loss, the FDA-approved tirzepatide formulation is Zepbound. Coverage for Zepbound follows the same pattern as Wegovy: covered on some plans, excluded on others.

How much does Wegovy cost with UnitedHealthcare insurance? When covered, Wegovy typically costs $100-250/month copay (Tier 4) or 25-40% coinsurance (Tier 5), which equals $300-560/month. Manufacturer copay cards can reduce this to $0-25/month for commercially insured patients. Without coverage, retail price is $1,349/month.

Does UnitedHealthcare Medicare Advantage cover GLP-1 for weight loss? No. Federal law prohibits Medicare from covering medications for weight loss. UnitedHealthcare Medicare Advantage plans cannot cover Wegovy or Zepbound. They do cover Ozempic and Mounjaro when prescribed for Type 2 diabetes.

What is the prior authorization process for GLP-1 medications with UnitedHealthcare? Your provider submits a prior authorization request through UnitedHealthcare's provider portal or by fax. The request must include diagnosis code, BMI, A1C (for diabetes), documentation of prior medication trials, and medical necessity justification. UnitedHealthcare responds within 3-7 business days. Approval rate is 65-82% depending on indication and documentation completeness.

Can I appeal a UnitedHealthcare denial for Wegovy? Yes. UnitedHealthcare has a two-level appeal process. Level 1 is internal review by UnitedHealthcare (30-day decision). Level 2 is external independent review (binding decision). However, appeals rarely succeed if the denial reason is a plan exclusion rather than medical necessity. Exclusions are plan design features that appeals cannot override.

Does UnitedHealthcare cover compounded semaglutide? No. UnitedHealthcare does not cover compounded medications under any plan type. Compounded semaglutide and tirzepatide are not FDA-approved drugs and are explicitly excluded from coverage. Patients using compounded GLP-1s pay out-of-pocket.

How do I check if my UnitedHealthcare plan covers GLP-1 medications? Log into your member portal, navigate to "Prescription Drug List," and search for the specific drug name. Check both the formulary tier and the plan's exclusion list in your Summary Plan Description. Call member services for verbal confirmation and request a written coverage determination for a binding answer.

What BMI do I need for UnitedHealthcare to cover weight-loss GLP-1s? UnitedHealthcare typically requires BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, or cardiovascular disease). These criteria match FDA labeling for Wegovy and Zepbound.

Does UnitedHealthcare cover Zepbound? Coverage depends on your specific plan. Zepbound (tirzepatide for weight loss) has similar coverage rates to Wegovy: approximately 38% of employer-sponsored plans cover it, 62% exclude it. When covered, it's typically placed on specialty tier (Tier 4 or 5) with high cost-sharing.

Can my doctor prescribe Ozempic off-label for weight loss and get UnitedHealthcare to cover it? No. UnitedHealthcare denies claims for off-label use of GLP-1 medications. The diagnosis code on the prescription must match an FDA-approved indication. Ozempic prescribed for weight loss (diagnosis code E66.x) will be denied even though Ozempic prescribed for diabetes (diagnosis code E11.x) would be covered.

How long does UnitedHealthcare prior authorization take for GLP-1 medications? Standard prior authorization decisions are issued within 3-7 business days. Urgent requests (rare for GLP-1s) are decided within 24 hours. If additional documentation is needed, UnitedHealthcare requests it within 3 days, and the clock resets once you provide it.

What happens to my GLP-1 coverage when I turn 65 and switch to UnitedHealthcare Medicare Advantage? You lose coverage for weight-loss GLP-1s (Wegovy, Zepbound) because Medicare excludes weight-loss medications by federal law. If you have Type 2 diabetes, you retain coverage for Ozempic or Mounjaro under the diabetes indication. This is a coverage cliff that affects all patients transitioning from commercial to Medicare plans.

Does UnitedHealthcare require step therapy before approving GLP-1 medications? Yes. For diabetes, you must try metformin plus one other oral agent for 90 days each before GLP-1 approval. For weight loss (when covered), you must complete a 6-month lifestyle modification program and trial phentermine or orlistat. Step-therapy exceptions are available for documented contraindications or prior failures.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Davies MJ et al. Gastric Emptying and Glycemic Control with Tirzepatide vs Dulaglutide. Diabetes Care. 2023.
4. Jain V et al. Employer Exclusions of Anti-Obesity Medications in Commercial Health Plans. Health Affairs. 2025.
5. Luo J et al. Patient-Reported Barriers to GLP-1 Receptor Agonist Access. JAMA Network Open. 2024.
6. UnitedHealthcare Medical Policy 2024T0598H: GLP-1 Receptor Agonists. Updated January 2026.
7. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6. 2025.
8. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
9. Garvey WT et al. American Association of Clinical Endocrinologists Guidelines for Obesity Management. Endocrine Practice. 2024.
10. Employers Health Coalition. Trends in Obesity Medication Coverage. Annual Report 2025.
11. Novo Nordisk. Wegovy Prescribing Information. Updated 2025.
12. Eli Lilly. Zepbound Prescribing Information. Updated 2025.
13. 42 U.S.C. § 1395w-102(e)(2)(A): Medicare Part D Excluded Drug Categories.
14. Congressional Budget Office. Cost Estimate for Treat and Reduce Obesity Act of 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. UnitedHealthcare is a registered trademark of UnitedHealth Group. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. Victoza and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.